Stocks
BioNTech SEBNTX
NASDAQHealthcareBiotechnology$96.73+1.21%
Price as of · delayed, not real-time
A German biotechnology company focused on developing immunotherapies for cancer and infectious diseases, BioNTech gained prominence through its COVID-19 vaccine partnership with Pfizer. The company's mRNA technology platform and pipeline of oncology candidates make it a key player in the biopharma space. Investors monitor BioNTech for its vaccine revenue streams and clinical trial progress in cancer treatments.
Market Cap: $22.9B52W Range: $79.52-$124.00
Congressional Interest in BioNTech SE (BNTX)
4 members of Congress have disclosed 14 trades in BioNTech SE (BNTX), a Healthcare company. The buy/sell breakdown shows 8 purchases versus 6 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
14
Unique Politicians
4
Buys
8
Sells
6
Who in Congress Is Trading BNTX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-08-07 | Valerie Hoyle | sell | $1K-$15K |
| 2024-09-03 | Josh Gottheimer | sell | $1K-$15K |
| 2024-08-30 | Josh Gottheimer | sell | $1K-$15K |
| 2024-04-15 | Josh Gottheimer | buy | $1K-$15K |
| 2024-03-14 | Josh Gottheimer | sell | $1K-$15K |
| 2024-03-09 | Josh Gottheimer | sell | $1K-$15K |
| 2023-12-07 | Josh Gottheimer | buy | $1K-$15K |
| 2023-12-06 | Josh Gottheimer | buy | $1K-$15K |
| 2023-12-05 | Josh Gottheimer | buy | $1K-$15K |
| 2016-06-12 | Kurt Schrader | sell | $1K-$15K |
| 2012-09-08 | Alan Grayson | buy | $50K-$100K |
| 2012-07-08 | Alan Grayson | buy | $50K-$100K |
| 2012-03-10 | Alan Grayson | buy | $15K-$50K |
| 2012-02-10 | Alan Grayson | buy | $50K-$100K |